QuidelOrtho Corporation
As of Oct 22, 2026, QuidelOrtho is in Stage 4, the downtrend phase, now in week 6 (since Sep 11, 2026). It closed at $13.48, 61.9% below its 52-week high and below its 200-day average, which is falling.
QuidelOrtho Corporation provides diagnostic testing solutions. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is QDEL early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
QDEL among Medical Devices95th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …95 | QDEL | Stage 4 · wk 6 | 21 | +30.4% |
QuidelOrtho: quick answers
What stage is QuidelOrtho in?
As of Oct 22, 2026, QuidelOrtho (QDEL) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 11, 2026 and is in week 6. What the four stages mean
Is QuidelOrtho in an uptrend?
No. QuidelOrtho is in a Stage 4 downtrend. It trades 20.0% below its 200-day average, which is falling.
How far is QuidelOrtho from its 52-week high?
QuidelOrtho closed at $13.48 on Oct 22, 2026, 61.9% below its 52-week high of $35.38. Its 52-week low is $9.96.
How has QuidelOrtho performed over the past year?
As of Oct 22, 2026, QuidelOrtho is down 54.8% over the past year and down 53.2% so far in 2026.
Which sector and industry is QuidelOrtho in?
QuidelOrtho is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.